Antiangiogenic drugs are currently standard of care in adults with renal cell carcinoma (RCC), including translocation RCC. Although antitumor activity and toxicity profile are well known in adults, few data have been reported in children. Here we present the case of a patient diagnosed at 2 years old with a metastatic translocation RCC, consecutively treated with 5 tyrosine kinase inhibitors during 6 years. The antitumor activity and toxic effects are described, and a brief review of the literature is presented.
Journal of pediatric hematology/oncology. 2017 Mar 23 [Epub ahead of print]
Irene Jiménez, Hervé J Brisse, Paul Fréneaux, Sabine Sarnacki, Jean Michon, Daniel Orbach, Gaelle Pierron, Nathalie Clément, François Doz, Bernard Escudier, Gudrun Schleiermacher
Departments of *Pediatric Oncology, Adolescents and Young Adults †Translational Research ‡Radiology §Pathology ¶Somatic Genetics ††INSERM U830 Research Center, Institut Curie ∥Department of Pediatric Surgery, Necker Enfants-Malades Hospital, Assistance Publique #Department of Pediatrics, University of Paris-Descartes, Sorbonne Paris Cité, Paris **Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France.